Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β–like signaling pathway
Lihua Ding, … , Cuifen Huang, Qinong Ye
Lihua Ding, … , Cuifen Huang, Qinong Ye
Published January 12, 2009
Citation Information: J Clin Invest. 2009;119(2):349-361. https://doi.org/10.1172/JCI35930.
View: Text | PDF
Research Article Oncology

Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β–like signaling pathway

  • Text
  • PDF
Abstract

The four-and-a-half LIM (FHL) proteins belong to a family of LIM-only proteins that regulate cell proliferation, differentiation, and apoptosis. The exact functions of each FHL protein in cancer development and progression remain unknown. Here we report that FHL1, FHL2, and FHL3 physically and functionally interact with Smad2, Smad3, and Smad4, important regulators of cancer development and progression, in a TGF-β–independent manner. Casein kinase 1δ, but not the TGF-β receptor, was required for the FHL-mediated TGF-β–like responses, including increased phosphorylation of Smad2/3, interaction of Smad2/3 and Smad4, nuclear accumulation of Smad proteins, activation of the tumor suppressor gene p21, and repression of the oncogene c-myc. FHL1–3 inhibited anchorage-dependent and -independent growth of a human hepatoma cell line in vitro and tumor formation in nude mice. Further analysis of clinical samples revealed that FHL proteins are often downregulated in hepatocellular carcinomas and that this correlates with decreased TGF-β–like responses. By establishing a link between FHL proteins and Smad proteins, this study identifies what we believe to be a novel TGF-β–like signaling pathway and indicates that FHL proteins may be useful molecular targets for cancer therapy.

Authors

Lihua Ding, Zhaoyun Wang, Jinghua Yan, Xiao Yang, Aijun Liu, Weiyi Qiu, Jianhua Zhu, Juqiang Han, Hao Zhang, Jing Lin, Long Cheng, Xi Qin, Chang Niu, Bin Yuan, Xiaohui Wang, Cui Zhu, Yan Zhou, Jiezhi Li, Haifeng Song, Cuifen Huang, Qinong Ye

×

Figure 3

FHL1 regulates TGF-β–responsive transcription and Smad2/3 phosphorylation in TGF-β– and TGF-β receptor–independent manners.

Options: View larger image (or click on image) Download as PowerPoint
FHL1 regulates TGF-β–responsive transcription and Smad2/3 phosphorylatio...
(A) HepG2 cells were cotransfected with p3TP-Lux and FHL1 or RBPMS, with or without 5 ng/ml TGF-β1, 10 μg/ml TGF-β–neutralizing antibody (α-TGF-β), or 1 μM SB-431542. Cells were analyzed as in Figure 2A. Values shown are mean ± SD of triplicate measurements and have been repeated 3 times with similar results. *P < 0.05 versus empty vector with TGF-β. **P < 0.01 versus RBPMS without TGF-β. #P < 0.05 versus FHL1 with TGF-β. ##P < 0.01 versus RBPMS with TGF-β. (B) T47D cells were transfected with FLAG-tagged FHL1 and treated with 5 ng/ml TGF-β1. Cell lysates were analyzed by immunoblot with anti–phospho-Smad2/3 (Ser423/425) (p-Smad2/3) or anti-Smad2/3. (C) Extracts were immunoprecipitated with anti-FLAG from FLAG-tagged FHL1- or RBPMS-expressing HepG2 cells, treated with 5 ng/ml TGF-β1 and 10 μM SB-431542. In vitro kinase assays were performed with His-Smad2, His-Smad3, His-Smad2(S465,467A) (His-Smad2Cm), His-Smad3(S423,425A) (His-Smad3Cm), His-Smad2(S249,254A) (His-Smad2Lm), or His-Smad3(S207,212A) (His-Smad3Lm) as substrate. The molecular weights were as follows: p-Smad2/3, ~56 kDa/51 kDa; Smad2/3, ~56 kDa/51 kDa; His-Smad2Cm, ~57 kDa; His-Smad2Lm, ~57 kDa; His-Smad3Cm, ~52 kDa; His-Smad3Lm, ~52 kDa.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts